GlassScriptPhysician profile
Daniel L Venarske
NPI 1003892357
$155,690.93
in general payments reported to CMS, 2019-2025
36 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $13K · 2022: $13K · 2023: $28K · 2024: $39K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Food and Beverage: $12K · Travel and Lodging: $3,684 · Education: $229 · Consulting Fee: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,047.00 |
| Food and Beverage | $12,051.23 |
| Travel and Lodging | $3,684.08 |
| Education | $229.43 |
| Consulting Fee | $197.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $75,931.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $61,050.78 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Pfizer INC. | $4,400.62 | 2019-2025 | |
| Genzyme Corporation | $2,948.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,719.27 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,899.14 | 2020-2025 | Cinryze, Cuvitru, Takhzyro |
| Csl Behring | $1,669.22 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $1,300.06 | 2019-2025 | |
| Genentech USA, INC. | $577.40 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $501.85 | 2023-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Amgen INC. | $460.02 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $423.84 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Adma Biomanufacturing LLC | $344.08 | 2022-2025 | |
| Kaleo, INC. | $196.07 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $168.71 | 2023-2025 | Orladeyo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $167.90 | 2022-2024 | Rinvoq |
| Leo Pharma INC. | $136.89 | 2022-2025 | Adbry, Anzupgo |
| Pharming Healthcare, INC. | $124.57 | 2019-2025 | Ruconest |
| Incyte Corporation | $78.53 | 2022-2024 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $74.92 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.08 | 2019-2023 | Spiriva Respimat |
| Shire North American Group INC | $55.25 | 2019 | |
| Argenx US, INC. | $51.99 | 2024 | Vyvgart |
| Ionis Pharmaceuticals, INC. | $50.44 | 2025 | Dawnzera |
| Genentech, INC. | $49.95 | 2021 | |
| Arcutis Biotherapeutics, INC. | $40.11 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $39.36 | 2021-2023 | |
| Qol Medical, LLC | $38.33 | 2024 | Sucraid |
| Blueprint Medicines Corporation | $31.80 | 2024 | Ayvakit |
| Mylan Specialty L.P. | $17.59 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $16.49 | 2025 | Neffy |
| Philips North America LLC | $14.91 | 2021 | |
| Lilly USA, LLC | $14.20 | 2025 | Ebglyss |
| Optinose US, INC. | $13.67 | 2024 | |
| Organon LLC | $12.51 | 2025 | |
| Cycle Pharmaceuticals INC | $12.21 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Venarske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.